N🟁N

30 am ET October 11, 2010 to Discuss New Collaboration and Updated Guidance for Fiscal Year 2011

  //health-fitness.news-articles.net/content/2010/ .. n-and-updated-guidance-for-fiscal-year-2011.html
  Published in Health and Fitness on Monday, October 11th 2010 at 3:20 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc. ] (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it will host a conference call at 8:30 am ET on Monday, October 11, 2010 to discuss the Company's new collaboration announced this morning and its updated financial guidance for ImmunoGena™s fiscal year ending June 30, 2011.

To access the live call by phone, dial 913-312-0658. Passcode is 4078495. The call also may be accessed through the Investor Information section of the Company's website, [ www.immunogen.com ]. Following the live webcast, a replay of the call will be available at the same location through October 18, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Companya™s expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Companya™s TAP technology uses monoclonal antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGena™s TAP technology, T-DM1, is in Phase III testing through the Companya™s collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].